↓ Skip to main content

Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)

Overview of attention for article published in European Journal of Cancer (1965), April 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter
14 tweeters
patent
3 patents
facebook
2 Facebook pages
wikipedia
1 Wikipedia page

Citations

dimensions_citation
232 Dimensions

Readers on

mendeley
482 Mendeley
Title
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
Published in
European Journal of Cancer (1965), April 2017
DOI 10.1016/j.ejca.2017.01.017
Pubmed ID
Authors

M.J. Duffy, N. Harbeck, M. Nap, R. Molina, A. Nicolini, E. Senkus, F. Cardoso

Abstract

Biomarkers play an essential role in the management of patients with invasive breast cancer. For selecting patients likely to respond to endocrine therapy, both oestrogen receptors (ERs) and progesterone receptors (PRs) should be measured on all newly diagnosed invasive breast cancers. On the other hand, for selecting likely response to all forms of anti-HER2 therapy (trastuzumab, pertuzumab, lapatinib or ado-trastuzumab emtansine), determination of HER2 expression or gene copy number is mandatory. Where feasible, measurement of ER, PR and HER2 should be performed on recurrent lesions and the primary invasive tumour. Although methodological problems exist in the determination of Ki67, because of its clearly established clinical value, wide availability and low costs relative to the available multianalyte signatures, Ki67 may be used for determining prognosis, especially if values are low or high. In oestrogen receptor (ER)-positive, HER2-negative, lymph node-negative patients, multianalyte tests such as urokinase plasminogen activator (uPA)-PAI-1, Oncotype DX, MammaPrint, EndoPredict, Breast Cancer Index (BCI) and Prosigna (PAM50) may be used to predict outcome and aid adjunct therapy decision-making. Oncotype DX, MammaPrint, EndoPredict and Prosigna may be similarly used in patients with 1-3 metastatic lymph nodes. All laboratories measuring biomarkers for patient management should use analytically and clinically validated assays, participate in external quality assurance programs, have established assay acceptance and rejection criteria, perform regular audits and be accredited by an appropriate organisation.

Twitter Demographics

The data shown below were collected from the profiles of 14 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 482 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
Canada 1 <1%
Unknown 480 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 77 16%
Student > Master 71 15%
Student > Bachelor 63 13%
Other 52 11%
Researcher 51 11%
Other 84 17%
Unknown 84 17%
Readers by discipline Count As %
Medicine and Dentistry 145 30%
Biochemistry, Genetics and Molecular Biology 99 21%
Agricultural and Biological Sciences 37 8%
Pharmacology, Toxicology and Pharmaceutical Science 16 3%
Engineering 15 3%
Other 62 13%
Unknown 108 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 August 2020.
All research outputs
#1,709,515
of 17,363,630 outputs
Outputs from European Journal of Cancer (1965)
#364
of 4,972 outputs
Outputs of similar age
#40,371
of 267,988 outputs
Outputs of similar age from European Journal of Cancer (1965)
#7
of 70 outputs
Altmetric has tracked 17,363,630 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,972 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,988 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.